# Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome

> **NCT00013689** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 8 (—)

## Conditions studied

- Autoimmune Disease
- Lymphoproliferative Disorder

## Interventions

- **DRUG:** Fansidar (pyrimethamine and sulfadoxine)

## Key facts

- **NCT ID:** NCT00013689
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-03
- **Primary completion:** —
- **Final completion:** 2003-03
- **Target enrollment:** 8 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00013689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00013689, "Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00013689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*